Mithra Signs Exclusive Agreement for Tibelia® in Canada

  • Tibelia® would be the first tibolone-based Hormone Therapy product available in Canada
  • Marketing authorization process is ongoing
  • Tibelia® already marketed in a number of countries through supply and license agreements

Liège, Belgium, 6 June 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, announces that it has signed an exclusive License and Supply Agreement for Tibelia®, its generic version of tibolone for use in Hormone Therapy (HT), with an undisclosed Canadian partner. Tibelia® is a generic version of Livial®.